Bio-Path Holdings Inc (NASDAQ: BPTH)’s stock price has dropped by -10.07 in relation to previous closing price of 0.93. Nevertheless, the company has seen a loss of -22.94% in its stock price over the last five trading days. globenewswire.com reported 2025-01-10 that Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides a clinical development and operational update for 2025. “The important work we conducted throughout 2024 has led us into what we believe is an exciting 2025 as we build off positive data generated in oncology and the addition of a new application for BP1001-A in the treatment of obesity for Type 2 Diabetes.
Is It Worth Investing in Bio-Path Holdings Inc (NASDAQ: BPTH) Right Now?
Company’s 36-month beta value is 0.09.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BPTH is 4.31M, and currently, short sellers hold a 5.80% ratio of that floaft. The average trading volume of BPTH on January 15, 2025 was 2.11M shares.
BPTH’s Market Performance
BPTH’s stock has seen a -22.94% decrease for the week, with a 17.48% rise in the past month and a -25.66% fall in the past quarter. The volatility ratio for the week is 16.84%, and the volatility levels for the past 30 days are at 22.74% for Bio-Path Holdings Inc The simple moving average for the past 20 days is -18.39% for BPTH’s stock, with a -49.51% simple moving average for the past 200 days.
Analysts’ Opinion of BPTH
Many brokerage firms have already submitted their reports for BPTH stocks, with ROTH Capital repeating the rating for BPTH by listing it as a “Buy.” The predicted price for BPTH in the upcoming period, according to ROTH Capital is $13 based on the research report published on March 11, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see BPTH reach a price target of $1.50, previously predicting the price at $4.50. The rating they have provided for BPTH stocks is “Buy” according to the report published on November 13th, 2017.
Maxim Group gave a rating of “Buy” to BPTH, setting the target price at $2 in the report published on August 10th of the previous year.
BPTH Trading at -6.10% from the 50-Day Moving Average
After a stumble in the market that brought BPTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.21% of loss for the given period.
Volatility was left at 22.74%, however, over the last 30 days, the volatility rate increased by 16.84%, as shares surge +19.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.35% lower at present.
During the last 5 trading sessions, BPTH fell by -22.94%, which changed the moving average for the period of 200-days by -79.21% in comparison to the 20-day moving average, which settled at $1.0293. In addition, Bio-Path Holdings Inc saw -27.59% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BPTH
Current profitability levels for the company are sitting at:
- -45.26 for the present operating margin
- 0.56 for the gross margin
The net margin for Bio-Path Holdings Inc stands at -38.37. The total capital return value is set at 30.24. Equity return is now at value -1159.74, with -263.29 for asset returns.
Based on Bio-Path Holdings Inc (BPTH), the company’s capital structure generated -0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -365.69. The debt to equity ratio resting at -0.04. The interest coverage ratio of the stock is -652.63.
Currently, EBITDA for the company is -15.76 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 11.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In a nutshell, Bio-Path Holdings Inc (BPTH) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
